Create a Journal Club on Zanidatamab in HER2+ Biliary Cancers

Created using ChatSlide

This presentation delves into the role of zanidatamab in treating HER2-driven biliary cancers, spotlighting the HERIZON-BTC-01 Phase 2b trial. Beginning with an overview of the HER2 mechanism in cancer and biliary cancer pathology, the outcomes and efficacy of zanidatamab, including a confirmed response rate of 41.3% and a median survival of 15.5 months, are discussed. The discussion extends to its safety profile, ensuring manageable adverse events and quality-of-life improvements. Future...